NZ552265A - Anti-rhesus D recombinant polyclonal antibody and methods of manufacture - Google Patents

Anti-rhesus D recombinant polyclonal antibody and methods of manufacture

Info

Publication number
NZ552265A
NZ552265A NZ552265A NZ55226505A NZ552265A NZ 552265 A NZ552265 A NZ 552265A NZ 552265 A NZ552265 A NZ 552265A NZ 55226505 A NZ55226505 A NZ 55226505A NZ 552265 A NZ552265 A NZ 552265A
Authority
NZ
New Zealand
Prior art keywords
rhd
cells
antibody
library
cell
Prior art date
Application number
NZ552265A
Other languages
English (en)
Inventor
Soren Kofoed Rasmussen
Anne Bondgaard Tolstrup
Soren Bregenholt Frederiksen
John Haurum
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of NZ552265A publication Critical patent/NZ552265A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ552265A 2004-07-20 2005-07-18 Anti-rhesus D recombinant polyclonal antibody and methods of manufacture NZ552265A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401133 2004-07-20
DKPA200401992 2004-12-22
PCT/DK2005/000501 WO2006007850A1 (en) 2004-07-20 2005-07-18 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture

Publications (1)

Publication Number Publication Date
NZ552265A true NZ552265A (en) 2009-04-30

Family

ID=35159789

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ552265A NZ552265A (en) 2004-07-20 2005-07-18 Anti-rhesus D recombinant polyclonal antibody and methods of manufacture

Country Status (13)

Country Link
US (2) US8198415B2 (https=)
EP (2) EP1771483A1 (https=)
JP (1) JP4926054B2 (https=)
KR (1) KR20070038556A (https=)
AU (1) AU2005263331B8 (https=)
BR (1) BRPI0513706A (https=)
CA (1) CA2574062A1 (https=)
EA (1) EA014182B1 (https=)
IL (1) IL179658A (https=)
MX (1) MX2007000644A (https=)
NO (1) NO20070927L (https=)
NZ (1) NZ552265A (https=)
WO (1) WO2006007850A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
SI1583830T1 (sl) * 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US8288109B2 (en) 2004-07-20 2012-10-16 Symphogen A/S Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
DK2121920T3 (da) * 2007-03-01 2011-11-21 Symphogen As Fremgangsmåde til kloning af sammenhørende antistoffer
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.
CA2695309A1 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
US20090093004A1 (en) * 2007-10-04 2009-04-09 Symphogen A/S Potency assay
RU2476886C2 (ru) * 2007-11-22 2013-02-27 Симфоген А/С Способ характеризации рекомбинантного поликлонального белка
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
NZ588651A (en) * 2008-04-23 2012-04-27 Symphogen As Methods for manufacturing a polyclonal protein
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110217317A1 (en) * 2008-08-26 2011-09-08 Symphogen A/S Treatment of thrombocytopenia
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN102137928A (zh) * 2008-08-29 2011-07-27 西福根有限公司 克隆禽源抗体的方法
BRPI0920032A2 (pt) * 2008-10-06 2017-06-27 Symphogen As método para identificar e selecionar candidatos a fármacos para produtos farmacológicos combinatórios
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
MX2012003538A (es) 2009-10-09 2012-08-03 Symphogen As Cuantificacion multiple de proteinas recombinantes individuales en una mezcla mediante peptidos distintivos y espectrometria de masas.
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
EP2864346B1 (en) * 2012-06-21 2018-10-17 Synthon Biopharmaceuticals B.V. Method of purifying an antibody
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
WO2017184973A1 (en) 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
ES2965352T3 (es) 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
EP3810649A1 (en) * 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
US12479908B2 (en) 2019-03-29 2025-11-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Antibodies against programmed cell death protein 1 (PD1) and uses thereof
JP7250950B2 (ja) 2019-03-29 2023-04-03 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法
CN118547004A (zh) 2019-06-19 2024-08-27 豪夫迈·罗氏有限公司 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
EP3986924A1 (en) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020294879A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CA3140323A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN114008212B (zh) 2019-06-19 2024-12-06 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生三价抗体表达细胞的方法
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
RU2770654C1 (ru) * 2021-06-17 2022-04-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ профилактики тяжелой формы гемолитической болезни новорожденных при резус-иммунизации у беременных с соматической патологией и потерями плода в анамнезе
WO2025039046A1 (en) * 2023-08-23 2025-02-27 The Walter And Eliza Hall Institute Of Medical Research Anti-rhesus d human monoclonal antibodies
CN119176879B (zh) * 2024-09-05 2025-08-05 西安市中心血站（陕西省血液中心） 一种中和抗d抗体的抗独特型抗体及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002413A1 (en) 1983-11-28 1985-06-06 The Board Of Trustees Of The Leland Stanford Jr. U HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
GB8722020D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722019D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722018D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
GB8906129D0 (en) 1989-03-17 1989-05-04 Central Blood Lab Authority Pharmaceutical preparations
GB8919761D0 (en) 1989-09-01 1989-10-18 Central Blood Lab Authority Chemical compounds
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
BR9305557A (pt) 1992-06-26 1997-03-25 Aetsrn Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
JP3731891B2 (ja) 1992-10-21 2006-01-05 ミルテンイ，ステファン 分泌生成物による細胞の直接選択
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
DE69534347T2 (de) * 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
AU722127B2 (en) 1996-06-24 2000-07-20 Zlb Behring Ag Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens, the DNA encoding them and the process for their preparation and use
US5876925A (en) * 1996-10-11 1999-03-02 The Trustees Of The University Of Pennsylvania Magnetically activated cell sorting for production of proteins
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
WO1999025821A1 (en) 1997-11-18 1999-05-27 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
AU771111B2 (en) 1998-07-21 2004-03-11 Emd Millipore Corporation A polynucleotide comprising a ubiquitous chromatin opening element (UCOE)
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
DK1234022T3 (da) 1999-07-23 2010-07-19 Univ California DNA-rekombination i eukaryote celler med bakteriofag PHIC31-rekombinationssystemet
EP1106625A1 (en) 1999-11-17 2001-06-13 ZLB Bioplasma AG Rhesus D specific peptide sequences
WO2001058925A2 (en) 2000-02-08 2001-08-16 The Regents Of The University Of Michigan Protein separation and display
US7069151B2 (en) 2000-02-08 2006-06-27 Regents Of The University Of Michigan Mapping of differential display of proteins
CA2401663C (en) 2000-02-08 2008-11-25 The Regents Of The University Of Michigan Protein mapping
HK1052305B (en) 2000-05-26 2007-10-12 Symphogen A/S Recombinant or purified polyclonal antibodies for treating allergy
BR0112633A (pt) 2000-07-21 2003-09-16 Us Agriculture Método para substituir, translocar e empilhar dna em genomas eucarióticos
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
JP2004514444A (ja) * 2000-11-28 2004-05-20 アプライド　モレキュラー　エボリューション，　インコーポレイテッド 二重ｌｏｘ組換えに基づく真核生物発現ライブラリーおよび使用方法
EP1739424B1 (en) 2000-12-26 2011-08-24 The Institute for Systems Biology Rapid and quantitative proteome anaysis and related methods
US20040033591A1 (en) 2002-05-31 2004-02-19 The Regents Of The University Of Michigan Automated protein analysis system
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
AU2003284227A1 (en) 2002-10-15 2004-05-04 The Regents Of The University Of Michigan Multidimensional protein separation system
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
SI1583830T1 (sl) * 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US8288109B2 (en) 2004-07-20 2012-10-16 Symphogen A/S Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line

Also Published As

Publication number Publication date
NO20070927L (no) 2007-04-19
EP1771483A1 (en) 2007-04-11
BRPI0513706A (pt) 2008-05-13
WO2006007850A1 (en) 2006-01-26
EP1967529A1 (en) 2008-09-10
AU2005263331B8 (en) 2011-06-16
AU2005263331A1 (en) 2006-01-26
IL179658A0 (en) 2007-05-15
US8198415B2 (en) 2012-06-12
US20090017017A1 (en) 2009-01-15
JP2008509658A (ja) 2008-04-03
US20120322690A1 (en) 2012-12-20
EA200700249A1 (ru) 2007-06-29
KR20070038556A (ko) 2007-04-10
IL179658A (en) 2011-08-31
CA2574062A1 (en) 2006-01-26
AU2005263331B2 (en) 2011-05-26
MX2007000644A (es) 2007-03-28
JP4926054B2 (ja) 2012-05-09
EA014182B1 (ru) 2010-10-29
AU2005263331A8 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
AU2005263331B2 (en) Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture
AU2004203727B2 (en) Method for manufacturing recombinant polyclonal proteins
KR101555658B1 (ko) 재조합 폴리클로날 단백질의 제조 방법
CA2554054C (en) Mixtures of binding proteins
US20060275766A1 (en) Method for manufacturing recombinant polyclonal proteins
AU2009336567A1 (en) Anti-RhD monoclonal antibodies
CN101023101A (zh) 抗－恒河猴d重组多克隆抗体和生产方法
CN100383244C (zh) 用于生产重组多克隆蛋白质的方法
AU2008201796A1 (en) Method for manufacturing recombinant polyclonal proteins
HK1078896B (en) Method for manufacturing recombinant polyclonal proteins
HK1134519B (en) Method for manufacturing a recombinant polyclonal protein

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed